SecBot SecBot
8-K ·Filed Nov 4, 2026

STE

STERIS plc
NEUTRAL
Impact 4/10
Horizonmonths Processed12d 3h ago SEC0001193125-26-447617
8-K with no item list reported
Actionable Insight • Neutral

Monitor the closing of the Xodus Medical acquisition and any subsequent drawdowns on the term loan and bridge facility. The leverage ratio covenant will be tested quarterly; watch for any material acquisition that could temporarily increase the permitted leverage to 3.75x.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$254.12
T+0 close · Nov 4, 2026 · via day close
Latest settled
−0.27%
T+5 · $253.44 · next T+20 in 17d
Vs SPY
−3.56%
α at T+5
Latest observation
+5.99%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $254.12entry
  2. T+1 · 11d ago −0.72%α −1.03% · $252.30
  3. T+5 · 5d ago −0.27%α −3.56% · $253.44
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

STERIS plc entered into a $1.6 billion revolving credit facility and a $500 million delayed draw term loan agreement on November 4, 2026, to refinance its existing credit facility and partially finance its acquisition of Xodus Medical, Inc. The new facilities increase STERIS's total available credit to $2.1 billion, supporting the acquisition and general corporate purposes.

Key Facts

  • STERIS entered into a $1.6 billion revolving credit facility and a $500 million delayed draw term loan agreement on November 4, 2026.
  • The new credit agreement refinances and terminates the existing $1.6 billion revolving credit agreement dated October 7, 2024.
  • The delayed draw term loan is specifically to finance, in part, the acquisition of Xodus Medical, Inc. (Target) pursuant to a Purchase and Sale Agreement dated October 11, 2026.
  • A $2.0 billion senior unsecured bridge facility is also available in connection with the acquisition.
  • The revolving credit facility matures in five years (November 4, 2031) and the term loan matures five years after the closing date.
  • Proceeds from the revolving facility may also be used for general corporate purposes and working capital.
  • The term loan has a ticking fee of 0.11% per annum starting 90 days after the effective date if the acquisition has not closed.
  • The credit agreements include financial covenants: maximum leverage ratio of 3.50x (increased by 0.25x after a material acquisition) and minimum interest coverage ratio of 3.00x.

Financial Impact

STERIS secured $2.1 billion in new credit facilities ($1.6B revolver + $500M term loan), refinancing its existing $1.6B revolver and providing dedicated funding for the Xodus Medical acquisition.

debtliquidityleverage

Risk Factors

  • The acquisition of Xodus Medical may not close, leaving the term loan undrawn and ticking fees payable.
  • Increased leverage from the acquisition could pressure credit ratings and increase borrowing costs under the Applicable Margin grid.
  • The bridge facility, if drawn, would further increase debt levels and interest expense.

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-447617
Document: d533343dex102.htm0001193125-26-447617

Track record

21 reports on STE

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.96% at T+20 after the Oct 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 23
  2. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $264.32 +4.29% settles Nov 19
  5. Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $264.32 +3.14% settles Nov 18
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Viewing Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
  9. Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $264.32 +13.86% ▲ +9.47% +14.19% vs SPY
  10. Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $264.32 +19.34% ▲ +3.17% +3.61% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (12h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026